269 related articles for article (PubMed ID: 25770888)
1. Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors.
Harris JP; Chang-Halpenny CN; Maxim PG; Quon A; Graves EE; Diehn M; Loo BW
Clin Lung Cancer; 2015 Nov; 16(6):475-85. PubMed ID: 25770888
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.
Zhao F; Ding G; Huang W; Li M; Fu Z; Yang G; Kong L; Zhang Y; Yu J
Clin Lung Cancer; 2015 Nov; 16(6):e111-9. PubMed ID: 25736696
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
[TBL] [Abstract][Full Text] [Related]
4. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.
Abelson JA; Murphy JD; Trakul N; Bazan JG; Maxim PG; Graves EE; Quon A; Le QT; Diehn M; Loo BW
Lung Cancer; 2012 Dec; 78(3):219-24. PubMed ID: 23009727
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.
Ong LT; Dunphy M; Foster A; Woo KM; Zhang Z; Perez CA; Pietanza CM; Rosenzweig KE; Gelblum DY; Rimner A; Wu AJ
Clin Lung Cancer; 2016 May; 17(3):184-8. PubMed ID: 26320828
[TBL] [Abstract][Full Text] [Related]
6. Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer.
Gensheimer MF; Hong JC; Chang-Halpenny C; Zhu H; Eclov NCW; To J; Murphy JD; Wakelee HA; Neal JW; Le QT; Hara WY; Quon A; Maxim PG; Graves EE; Olson MR; Diehn M; Loo BW
Radiother Oncol; 2017 Nov; 125(2):338-343. PubMed ID: 28830717
[TBL] [Abstract][Full Text] [Related]
7. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
8. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.
Kishimoto M; Iwano S; Ito S; Kato K; Ito R; Naganawa S
Lung Cancer; 2014 Nov; 86(2):180-4. PubMed ID: 25263854
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung.
Roy S; Pathy S; Kumar R; Mohanti BK; Raina V; Jaiswal A; Taywade S; Garg K; Thulkar S; Mohan A; Mathur S; Behera D
Nucl Med Commun; 2016 Feb; 37(2):129-38. PubMed ID: 26544097
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
Hasselle MD; Haraf DJ; Rusthoven KE; Golden DW; Salgia R; Villaflor VM; Shah N; Hoffman PC; Chmura SJ; Connell PP; Vokes EE; Weichselbaum RR; Salama JK
J Thorac Oncol; 2012 Feb; 7(2):376-81. PubMed ID: 22198429
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pre-treatment
Aktan M; Koc M; Kanyilmaz G; Yavuz BB
Ann Nucl Med; 2017 Jul; 31(6):462-468. PubMed ID: 28516335
[TBL] [Abstract][Full Text] [Related]
15. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
16. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
Coon D; Gokhale AS; Burton SA; Heron DE; Ozhasoglu C; Christie N
Clin Lung Cancer; 2008 Jul; 9(4):217-21. PubMed ID: 18650169
[TBL] [Abstract][Full Text] [Related]
17. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
18. Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.
Takahashi N; Yamamoto T; Matsushita H; Sugawara T; Kubozono M; Umezawa R; Ishikawa Y; Kozumi M; Katagiri Y; Tasaka S; Takeda K; Takeda K; Dobashi S; Jingu K
J Radiat Res; 2016 Nov; 57(6):655-661. PubMed ID: 27422935
[TBL] [Abstract][Full Text] [Related]
19. Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?
Akagunduz OO; Savas R; Yalman D; Kocacelebi K; Esassolak M
Nucl Med Biol; 2015 Nov; 42(11):899-904. PubMed ID: 26275933
[TBL] [Abstract][Full Text] [Related]
20. Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
Campeau MP; Herschtal A; Wheeler G; Mac Manus M; Wirth A; Michael M; Hogg A; Drummond E; Ball D
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1371-5. PubMed ID: 19250769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
